Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis.

The aim of this non-interventional, observational, multicentre, open-label study was to assess the effectiveness of a vaginal gel containing extracts of Thymus vulgaris and Eugenia caryophyllus in conjunction with two specific lactobacilli strains (Lactobacillus fermentum LF10 and Lactobacillus plantarum LP02) specifically formulated in slow-release vaginal capsules, in treating bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) or recurrent vulvovaginal candidiasis disease (RVVC) [Estromineral Probiogel (EPB) in Italy, or Saugella Probiogel; Meda Pharma - Mylan Group]. There was a statistically significant improvement in pruritus, burning, vulvovaginal oedema and erythema, dyspareunia and vaginal secretions in all diagnostic groups. At the end of the study, the microbiological evaluation was normal in 80.0% of cases with BV, 62.5% of cases with VVC and 100.0% with RVVC. The clinical data allow EPB to be recommended in the acute treatment of VVC and BV, suggesting that EPB is a useful maintenance treatment if there are recurrent episodes. Controlled studies are needed to confirm the efficacy of EPB in the treatment of recurrences and to identify the most appropriate dosage regimen.

[1]  G. Ventolini Vaginal Lactobacillus: biofilm formation in vivo – clinical implications , 2015, International journal of women's health.

[2]  P. Nyirjesy Management of persistent vaginitis. , 2014, Obstetrics and gynecology.

[3]  R. Windrim,et al.  Best Practice & Research Clinical Obstetrics and Gynaecology , 2014 .

[4]  J. B. Startek,et al.  Prebiotics to Fight Diseases: Reality or Fiction? , 2013, Phytotherapy research : PTR.

[5]  A. Swidsinski,et al.  The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment , 2013, Current opinion in infectious diseases.

[6]  M. S. Juárez Tomás,et al.  Screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components , 2012, Journal of applied microbiology.

[7]  Dror Marchaim,et al.  Fluconazole-Resistant Candida albicans Vulvovaginitis , 2012, Obstetrics and gynecology.

[8]  G. Reid,et al.  Disruption of urogenital biofilms by lactobacilli. , 2011, Colloids and surfaces. B, Biointerfaces.

[9]  P. Braga,et al.  Inhibitory activity of thymol on native and mature Gardnerella vaginalis biofilms: in vitro study , 2010, Arzneimittelforschung.

[10]  P. Braga,et al.  Thymol inhibits Candida albicans biofilm formation and mature biofilm. , 2008, International journal of antimicrobial agents.

[11]  J. Marrazzo,et al.  Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis , 2007, Journal of Clinical Microbiology.

[12]  P. Braga Thymol: antibacterial, antifungal and antioxidant activities , 2005 .

[13]  Matthew R. Anderson,et al.  Evaluation of vaginal complaints. , 2004, JAMA.

[14]  P. Nyirjesy,et al.  Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole , 2002 .

[15]  Mahmoud A. Ghannoum,et al.  Biofilm Formation by the Fungal PathogenCandida albicans: Development, Architecture, and Drug Resistance , 2001, Journal of bacteriology.

[16]  N. Didry,et al.  Activity of thymol, carvacrol, cinnamaldehyde and eugenol on oral bacteria. , 1994, Pharmaceutica acta Helvetiae.